Seeing from the Inside Out
Nuclear imaging requires small amounts of radioactive materials called radiopharmaceuticals – injected, inhaled or swallowed – to diagnose disease. Clinicians utilize specialized imaging cameras, either single photon emission computed tomography (SPECT) or positron emission tomography (PET), designed to capture radiation emitted by radiopharmaceuticals.
Radiopharmaceuticals consist of a radioisotope (such as technetium) paired with a molecular agent (such as Lantheus’ Cardiolite® or NEUROLITE®) designed to localize in specific organs and tissues. Computers are used to generate detailed images of the areas of interest. The resulting images provide clinicians with important information on both the structure and function of the internal organs or tissues being imaged.
Myocardial Perfusion Imaging
Myocardial perfusion imaging (MPI) is a non-invasive test that utilizes a radiopharmaceutical injected into the body. The distribution of the radiopharmaceutical is captured using a specialized camera (most commonly SPECT), and the resulting images reveal the distribution of blood flow (perfusion) through the heart. MPI is typically conducted under both rest and stress conditions, after which physicians examine and compare the two scans to access whether the patient exhibits coronary artery disease.
PET imaging, also called a PET scan, has gained considerable support and use in the field of cardiovascular imaging. Unlike computed tomography (CT) or magnetic resonance imaging (MRI), which primarily show anatomy and structure, PET provides information about the function and metabolism of the body’s organs. PET offers many advantages to SPECT, including higher spatial and contrast resolution, which results in higher image quality and improved diagnostic accuracy.
Lantheus’ flurpiridaz F 18, a PET MPI agent in phase 3 development, has the potential to significantly improve the evaluation of Coronary Artery Disease (CAD).
The Expansion of MPI
- We were the first to commercially launch Thallium-201 in 1977
- First non-invasive method to assess blood flow to the heart and function of the myocardium
- The first technetium-labeled myocardial perfusion agent to provide physicians with prognostic information
- An expanded imaging window compared to Thallium-201 allows for a more detailed evaluation
Flurpiridaz F 18
- Our PET MPI agent currently in Phase 3 development, which may help better evaluate coronary artery disease
- Potential to provide improved image quality, increased diagnostic certainty and reduced patient radiation exposure over current SPECT MPI agents